MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 186 filers reported holding MYRIAD GENETICS INC in Q2 2023. The put-call ratio across all filers is 0.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $258,585 | +16.3% | 16,124 | +68.1% | 0.00% | – |
Q2 2023 | $222,328 | +3.9% | 9,593 | +4.1% | 0.00% | – |
Q1 2023 | $213,980 | -33.3% | 9,213 | -58.3% | 0.00% | -100.0% |
Q4 2022 | $320,785 | -23.1% | 22,103 | +1.3% | 0.00% | 0.0% |
Q3 2022 | $417,000 | +10.0% | 21,815 | +4.8% | 0.00% | 0.0% |
Q2 2022 | $379,000 | -22.3% | 20,824 | +7.5% | 0.00% | 0.0% |
Q1 2022 | $488,000 | +3.4% | 19,365 | +13.3% | 0.00% | 0.0% |
Q4 2021 | $472,000 | -35.0% | 17,093 | -24.1% | 0.00% | -50.0% |
Q3 2021 | $726,000 | +31.8% | 22,511 | +25.2% | 0.00% | +100.0% |
Q2 2021 | $551,000 | -9.5% | 17,987 | -10.0% | 0.00% | 0.0% |
Q1 2021 | $609,000 | +128.9% | 19,975 | +48.3% | 0.00% | 0.0% |
Q4 2020 | $266,000 | +44.6% | 13,471 | -4.4% | 0.00% | 0.0% |
Q3 2020 | $184,000 | +13.6% | 14,089 | -1.5% | 0.00% | 0.0% |
Q2 2020 | $162,000 | +19.1% | 14,300 | +50.8% | 0.00% | 0.0% |
Q1 2020 | $136,000 | – | 9,485 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |